Jupiter Life Line Hospitals Limited (NSE:JLHL) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year

Shareholders might have noticed that Jupiter Life Line Hospitals Limited (NSE:JLHL) filed its quarterly result this time last week. The early response was not positive, with shares down 3.8% to ₹1,590 in the past week. Results were roughly in line with estimates, with revenues of ₹3.2b and statutory earnings per share of ₹28.65. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

View our latest analysis for Jupiter Life Line Hospitals

Taking into account the latest results, the current consensus from Jupiter Life Line Hospitals' five analysts is for revenues of ₹15.1b in 2026. This would reflect a decent 20% increase on its revenue over the past 12 months. Per-share earnings are expected to soar 31% to ₹38.64. Before this earnings report, the analysts had been forecasting revenues of ₹14.9b and earnings per share (EPS) of ₹39.04 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

There were no changes to revenue or earnings estimates or the price target of ₹1,681, suggesting that the company has met expectations in its recent result. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic Jupiter Life Line Hospitals analyst has a price target of ₹1,920 per share, while the most pessimistic values it at ₹1,570. With such a narrow range of valuations, the analysts apparently share similar views on what they think the business is worth.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Jupiter Life Line Hospitals' past performance and to peers in the same industry. We can infer from the latest estimates that forecasts expect a continuation of Jupiter Life Line Hospitals'historical trends, as the 16% annualised revenue growth to the end of 2026 is roughly in line with the 19% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 19% annually. It's clear that while Jupiter Life Line Hospitals' revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at ₹1,681, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on Jupiter Life Line Hospitals. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Jupiter Life Line Hospitals analysts - going out to 2027, and you can see them free on our platform here.

You can also see our analysis of Jupiter Life Line Hospitals' Board and CEO remuneration and experience, and whether company insiders have been buying stock.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.